

Canada Cell Therapy Manufacturing Market By Therapy (T-Cell Therapies, Dendritic Cell Therapies, Tumor Cell Therapies, Stem Cell Therapies), By Source of Cell (Autologous v/s Allogenic), By Source (In-House v/s Contract Manufacturing), By Application (Oncology, Cardiovascular Diseases, Orthopedic Diseases, Others), By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others), and By Region, Competition, Forecast & Opportunities, 2018-2028F

Market Report (3 business days) | 2023-10-03 | 73 pages | TechSci Research

AVAILABLE LICENSES:

- Single User License \$3500.00
- Multi-User License \$4500.00
- Custom Research License \$7500.00

Report description:

Canada cell therapy manufacturing market is anticipated to witness impressive growth during the forecast period. This can be ascribed to the high prevalence of cancer and other target diseases and increasing R&D investments in pharmaceutical companies across the region. Similarly, increasing number of clinical trials and approval of stem cell-based therapies from regulatory bodies will further drive the growth of the Canada cell therapy manufacturing market during the forecast period. Also, growing financial assistance from governments, private vendors, and NGOs are anticipated to propel the growth of the Canada cell therapy manufacturing market during the forecast period. Manufacturers are involved in developing and launching various types of technologies for cell therapy manufacturing, which will further propel the growth of the Canada cell therapy manufacturing market during the forecast period.

Increasing Prevalence of Chronic Diseases

The increasing prevalence of chronic diseases is a major driver for the growth of the Canada cell therapy manufacturing market. Chronic diseases such as cancer, diabetes, cardiovascular diseases, and neurological disorders are among the leading causes of

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

death and disability across the world. Traditional treatments for these diseases, such as chemotherapy, radiation therapy, and surgery, have limitations and may not always be effective. As a result, there is a growing interest in cell-based therapies that offer the potential for more targeted and effective treatments. Cell therapies are a promising new approach to treating chronic diseases. They involve using living cells to replace or repair damaged or diseased cells in the body. Cell therapies have shown promising results in treating a variety of conditions, including cancer, heart disease, and neurological disorders. As such, the increasing prevalence of chronic diseases has created a growing demand for cell-based therapies. In Canada, the increasing prevalence of chronic diseases has led to a greater focus on developing innovative cell-based therapies. Canadian researchers and companies are actively working to develop new cell therapies and are making significant progress in this area. The Canadian government is also investing in research and development to support the growth of the cell therapy industry.

Supportive Government Policies

Supportive government policies are a key driver for the growth of the Canada cell therapy manufacturing market. The government provides funding for research and development in the field of cell therapy. This funding supports basic and applied research that is focused on developing new cell-based therapies and advancing existing ones. The government offers tax incentives for companies that invest in research and development, as well as those that invest in the production and commercialization of cell-based therapies. These incentives help to reduce the costs of developing and manufacturing these therapies. The government offers grants and funding to startups and small businesses that are focused on developing cell-based therapies. This support helps to reduce the barriers to entry for smaller companies and encourages innovation in the industry. The government is investing in infrastructure and workforce development to support the growth of the cell therapy industry. This includes funding for research facilities, manufacturing facilities, and training programs for workers in the industry.

Technological Advancements

Technological advancements are a major driver for the growth of the Canada cell therapy manufacturing market. Advances in cell biology, genetics, and engineering have paved the way for the development of new and innovative cell-based therapies that will drive the growth of the market during the forecast period. Technological advancements have led to a better understanding of how cells work and how they can be used to treat diseases. This has paved the way for the development of new and innovative cell-based therapies that are more effective and have fewer side effects than traditional treatments. Gene editing and gene therapy are emerging as promising new approaches to treat diseases. These technologies enable researchers to modify the genetic material of cells to correct genetic defects or enhance their therapeutic potential. Technological advancements have led to the development of new manufacturing processes for cell-based therapies. These processes are more efficient, scalable, and cost-effective than traditional manufacturing methods, making it easier to produce cell-based therapies at a commercial scale. Automation and robotics are being integrated into the cell therapy manufacturing process, improving the efficiency and reliability of the manufacturing process. This has led to reduced costs, faster production times, and improved quality control.

Research and Development

Research and development (R&D) are key drivers of the growth of the Canada cell therapy manufacturing market. The development of new and innovative cell-based therapies requires significant investment in R&D to discover and develop new therapies, optimize manufacturing processes, and demonstrate safety and efficacy through clinical trials. R&D is driving the development of new cell therapies that can be used to treat a wide range of diseases, including cancer, heart disease, and neurological disorders. This includes the identification and characterization of new cell types, as well as the development of new technologies for manipulating and engineering cells. R&D is also focused on optimizing manufacturing processes to improve the efficiency, scalability, and cost-effectiveness of cell therapy production. This includes the development of new technologies for culturing and expanding cells, as well as the integration of automation and robotics to streamline the manufacturing process. R&D is also critical for demonstrating the safety and efficacy of cell-based therapies through clinical trials. These trials are necessary to obtain regulatory approval and to bring new therapies to market. R&D is often conducted through collaboration and partnerships

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

between academia, industry, and government. These collaborations bring together expertise from different fields and help to accelerate the development of new therapies and technologies.

Growing Demand for Personalized Medicines

The growing demand for personalized medicines is a key driver for the growth of the Canada cell therapy manufacturing market. Personalized medicine refers to the use of a patient's genetic information, lifestyle, and other factors to tailor treatments to their individual needs. Cell-based therapies are particularly well-suited for personalized medicine because they can be customized to a patient's specific condition and genetic profile. Cell-based therapies can be tailored to a patient's specific condition and genetic profile, making them ideal for personalized medicines. Advances in cell biology, gene editing, and other technologies are making it possible to develop patient-specific therapies that are more effective and have fewer side effects than traditional treatments. Precision medicine is an approach to healthcare that emphasizes the customization of treatments to individual patients. Cell-based therapies are an important component of precision medicine, and the growing demand for personalized medicine is driving increased investment in this area. The growing demand for personalized medicine is driving the expansion of cell therapy applications beyond traditional areas such as cancer and blood disorders. Cell-based therapies are being developed for a wide range of conditions, including autoimmune diseases, neurological disorders, and cardiovascular disease. The demand for personalized medicine is also driving changes in regulatory and reimbursement policies. Regulators and payers are increasingly recognizing the value of personalized medicine and are working to create a regulatory and reimbursement framework that supports the development and commercialization of these therapies.

Market Segmentation

The Canada cell therapy manufacturing market can be segmented by therapy, source of cell, source, application, end user, and region. Based on therapy, the Canada cell therapy manufacturing market can be segmented into T-Cell therapies, dendritic cell therapies, tumor cell therapies, and stem cell therapies. Based on source of cell, the Canada cell therapy manufacturing market can be divided into autologous v/s allogenic. Based on source, the Canada cell therapy manufacturing market can be divided into in-house v/s contract manufacturing. Based on application, the Canada cell therapy manufacturing market can be segmented into oncology, cardiovascular diseases, orthopedic diseases, and others. Based on end user, the Canada cell therapy manufacturing market can be grouped into pharmaceutical & biotechnology companies, academic & research institutes, and others.

Market Players

Novartis Pharmaceuticals Canada Inc, Hoffmann-La Roche Ltd., Gilead Sciences Inc, Thermo Fisher Scientific Inc, Catalent Ontario Ltd., Takeda Canada Inc., and Amgen Canada Inc. are some of the leading players operating in the Canada cell therapy manufacturing market.

Report Scope:

In this report, the Canada cell therapy manufacturing market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

☐☐Canada Cell Therapy Manufacturing Market, By Therapy:

- o☐T-Cell Therapies
- o☐Dendritic Cell Therapies
- o☐Tumor Cell Therapies
- o☐Stem Cell Therapies

☐☐Canada Cell Therapy Manufacturing Market, By Source of Cell:

- o☐Autologous
- o☐Allogenic

☐☐Canada Cell Therapy Manufacturing Market, By Source:

- o☐In-House
- o☐Contract Manufacturing

☐☐Canada Cell Therapy Manufacturing Market, By Application:

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- o Oncology
- o Cardiovascular Diseases
- o Orthopedic Diseases
- o Others
- Canada Cell Therapy Manufacturing Market, By End User:
 - o Pharmaceutical & Biotechnology Companies
 - o Academic & Research Institutes
 - o Others

- Canada Cell Therapy Manufacturing Market, By Region:
 - o Ontario region
 - o Quebec region
 - o Alberta region
 - o British Columbia region
 - o Saskatchewan and Manitoba region
 - o Rest of Canada

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Canada cell therapy manufacturing market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

- Detailed analysis and profiling of additional market players (up to five).

Table of Contents:

1. Product Overview
 - 1.1. Market Definition
 - 1.2. Scope of the Market
 - 1.2.1. Markets Covered
 - 1.2.2. Years Considered for Study
 - 1.2.3. Key Market Segmentations
2. Research Methodology
 - 2.1. Objective of the Study
 - 2.2. Baseline Methodology
 - 2.3. Key Industry Partners
 - 2.4. Major Association and Secondary Types
 - 2.5. Forecasting Methodology
 - 2.6. Data Triangulation & Validation
 - 2.7. Assumptions and Limitations
3. Executive Summary
 - 3.1. Overview of the Market
 - 3.2. Overview of Key Market Segmentations
 - 3.3. Overview of Key Market Players
 - 3.4. Overview of Key Regions/Countries
 - 3.5. Overview of Market Drivers, Challenges, and Trends
4. Voice of Customer
5. Canada Cell Therapy Manufacturing Market Outlook
 - 5.1. Market Size & Forecast

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.1.1. By Value
- 5.2. Market Share & Forecast
 - 5.2.1. By Therapy (T-Cell Therapies, Dendritic Cell Therapies, Tumor Cell Therapies, Stem Cell Therapies)
 - 5.2.2. By Source of Cell (Autologous v/s Allogenic)
 - 5.2.3. By Source (In-House v/s Contract Manufacturing)
 - 5.2.4. By Application (Oncology, Cardiovascular Diseases, Orthopedic Diseases, Others)
 - 5.2.5. By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others)
 - 5.2.6. By Region (Quebec, Ontario, Alberta, British Columbia, Saskatchewan & Manitoba, Rest of Canada)
 - 5.2.7. By Company (2022)
- 5.3. Market Map
- 6. Canada Oncology Diseases Market Outlook
 - 6.1. Market Size & Forecast
 - 6.1.1. By Value
 - 6.2. Market Share & Forecast
 - 6.2.1. By Therapy
 - 6.2.2. By Source of Cell
 - 6.2.3. By Scale of Operation
 - 6.2.4. By Source
 - 6.2.5. By End User
- 7. Canada Cardiovascular Diseases Market Outlook
 - 7.1. Market Size & Forecast
 - 7.1.1. By Value
 - 7.2. Market Share & Forecast
 - 7.2.1. By Therapy
 - 7.2.2. By Source of Cell
 - 7.2.3. By Scale of Operation
 - 7.2.4. By Source
 - 7.2.5. By End User
- 8. Canada Orthopedic Diseases Market Outlook
 - 8.1. Market Size & Forecast
 - 8.1.1. By Value
 - 8.2. Market Share & Forecast
 - 8.2.1. By Therapy
 - 8.2.2. By Source of Cell
 - 8.2.3. By Scale of Operation
 - 8.2.4. By Source
 - 8.2.5. By End User
- 9. Market Dynamics
 - 9.1. Drivers
 - 9.2. Challenges
- 10. Market Trends & Developments
 - 10.1. Merger & Acquisition
 - 10.2. Product Development
 - 10.3. Recent Developments
- 11. Policy & Regulatory Landscape
- 12. Porters Five Forces Analysis
 - 12.1. Competition in the Industry

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 12.2.□Potential of New Entrants
 - 12.3.□Power of Suppliers
 - 12.4.□Power of Customers
 - 12.5.□Threat of Substitute Products
 - 13.□Canada Economic Profile
 - 14.□Competitive Landscape
 - 14.1.□Business Overview
 - 14.2.□Company Snapshot
 - 14.3.□Products & Services
 - 14.4.□Financials (As Reported)
 - 14.5.□Recent Developments
 - 14.5.1.□Novartis Pharmaceuticals Canada Inc
 - 14.5.2.□Hoffmann-La Roche Ltd.
 - 14.5.3.□Gilead Sciences Inc
 - 14.5.4.□Thermo Fisher Scientific Inc
 - 14.5.5.□Catalent Ontario Ltd.
 - 14.5.6.□Takeda Canada Inc.
 - 14.5.7.□Amgen Canada Inc.
 - 15.□Strategic Recommendations
- About Us & Disclaimer

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Canada Cell Therapy Manufacturing Market By Therapy (T-Cell Therapies, Dendritic Cell Therapies, Tumor Cell Therapies, Stem Cell Therapies), By Source of Cell (Autologous v/s Allogenic), By Source (In-House v/s Contract Manufacturing), By Application (Oncology, Cardiovascular Diseases, Orthopedic Diseases, Others), By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others), and By Region, Competition, Forecast & Opportunities, 2018-2028F

Market Report (3 business days) | 2023-10-03 | 73 pages | TechSci Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$3500.00
	Multi-User License	\$4500.00
	Custom Research License	\$7500.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*

Phone*

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-06-09"/>
		Signature	<input type="text"/>